Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes

Annals of Hematology

Volumn 91, Issue 11, 2012, Pages 1823-1824

  Salaroli, Adriano ^a   Loglisci, Giuseppina ^a   Serrao, Alessandra ^a   Alimena, Giuliana ^a   Breccia, Massimo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; IMATINIB; INSULIN;

ADULT; CASE REPORT; CHROMOSOME ANALYSIS; CHRONIC DISEASE; DIABETES CONTROL; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; FUSION GENE; GENE REARRANGEMENT; GLUCOSE HOMEOSTASIS; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LETTER; LEUKOCYTOSIS; MALE; METAPHASE; MYELOPROLIFERATIVE DISORDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; TEL PDGFR BETA GENE;

ADULT; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DRUG INTERACTIONS; DRUG MONITORING; GENE REARRANGEMENT; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MYELOPROLIFERATIVE DISORDERS; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84867330680     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1493-3     Document Type: Letter

References (10)

1. Mokhtari D, Welsh N (2009) Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes. Clin Sci (Lond) 118:241-247
2. Agostino NM, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, Sivik J, Drabick JJ (2011) Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and non-diabetic patients in general clinical practice. J Oncol Pharm Pract 17:197-202
3. Breccia M, Muscaritoli M, Aversa Z, Mandelli F, Alimena G (2004) Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. J Clin Oncol 22:4653-4655
4. Breccia M, Alimena G (2009) The metabolic consequences of imatinib mesylate: changes on glucose, lypidic and bone metabolism. Leuk Res 33:871-875
5. Guiteau J, Fanucchi M, Folpe A, Staley CA 3rd, Kooby DA (2006) Hypoglycemia in the setting of advanced gastrointestinal stromal tumor. Am Surg 72:1225-1230
6. Hamberg P, de Jong FA, Boonstra JG, van Doorn J, Verweji J, Sleijfer S (2006) Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib. J Clin Oncol 24:e30-e31
7. Hägerkvist R, Sandler S, Mokhtari D, Welsh N (2007) Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic pre-conditioning. FASEB J 21:618-628
8. Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino AC (2010) Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocrinol Metab 95:3763-3767
9. Dingli D, Wolf RC, Vella A (2007) Imatinib and type 2 diabetes. Endocr Pract 13:126-130
10. Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA (2008) Tyrosine kinase inhibitors reverse type 1 diabetes in non-obese diabetic mice. Proc Natl Acad Sci U S A 105:18895-18900